Krystal Biotech (KRYS) Cash from Operations (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Cash from Operations of 74789000.0 for Q2 2026, up 41.84% year-over-year from 52729000.0 in Q2 2025, and down 6.96% on a QoQ basis from 80382000.0 in Q1 2026.
Krystal Biotech (KRYS) Cash from Operations (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Cash from Operations for 11 years, with the latest figure at 74789000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 74789000.0, up 41.84% year-over-year; the trailing twelve-month figure through Jun 2026 was 272338000.0 (up 39.38% YoY), and the FY2025 annual result was 200865000.0, up 62.75% from the prior year.
- Cash from Operations fell to 74789000.0 in Q2 2026, from 80382000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 80382000.0 in Q1 2026 and troughed at 43059000.0 in Q2 2022.
- A 5-year average of 16115722.22 and a median of 5860000.0 in 2024 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2022, when Cash from Operations tumbled 325.11%; it then surged 1365.09% in 2025.
- A 5-year view of Cash from Operations shows it stood at 22329000.0 in 2022, then jumped by 67.61% to 7232000.0 in 2023, then jumped by 830.68% to 52843000.0 in 2024, then surged by 46.68% to 77508000.0 in 2025, then declined by 3.51% to 74789000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 74789000.0 in Q2 2026, 80382000.0 in Q1 2026, and 77508000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 74.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.79 Mn |
| Jun 30, 2026 | 74.79 Mn |
| Mar 31, 2026 | 80.38 Mn |
| Mar 31, 2026 | 80.38 Mn |
| Dec 31, 2025 | 77.51 Mn |
| Dec 31, 2025 | 77.51 Mn |
| Sep 30, 2025 | 39.66 Mn |
| Sep 30, 2025 | 39.66 Mn |
| Jun 30, 2025 | 52.73 Mn |
| Jun 30, 2025 | 52.73 Mn |
| Mar 31, 2025 | 30.97 Mn |
| Mar 31, 2025 | 30.97 Mn |
| Dec 31, 2024 | 52.84 Mn |
| Dec 31, 2024 | 52.84 Mn |
| Sep 30, 2024 | 58.86 Mn |
| Sep 30, 2024 | 58.86 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | 15.89 Mn |
| Mar 31, 2024 | 15.89 Mn |